ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

EBS vs SPRY // NET PROFIT MARGIN

Emergent BioSolutions Inc. (NYSE) VS. ARS Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: EBS 7 — SPRY 1
▲ NET PROFIT MARGIN LEADER: EBS
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EBS VS. SPRY) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC EBS SPRY SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 56.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 8.90% -35.00% +43.90 EBS /roic <GO>
EV/EBITDA & P/E Valuation 6.6x — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin 13.50% -60.00% +73.50 EBS /operating-margins <GO>
Net Profit Margin ACTIVE 7.10% -60.00% +67.10 EBS /net-margins <GO>
Revenue Growth (YoY) -28.80% -5.50% -23.30 SPRY /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.41 0.20 +1.21 EBS /balance-sheet <GO>
Piotroski F-Score Quality 8/9 2/9 +6.00 EBS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.0 29.8 +23.20 EBS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 6.5x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $370.2M $364.0M $6.2M EBS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR EBS REV SPRY REV EBS GROSS % SPRY GROSS % EBS FCF SPRY FCF
FY 2025 $742.9M $84.3M 56.1% — $156.8M -$171.2M
FY 2024 $1.04B $89.1M 34.7% — $35.8M $13.0M
FY 2023 $1.05B $30.0K — — -$206.3M -$59.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EBS // BETA —
SPRY // BETA —